Real‐World Use of Lecanemab in Patients With Early Alzheimer’s Disease in the United States: a Case Series Review
Overall, these findings underscore the benefits and safety profile of lecanemab in a real-world clinical setting. The majority of patients did not progress to the next disease stage during the follow-up period, with an average treatment duration exceeding a year (interim data). In a majority APOE ε4 carrier population, 11% of patients experienced an ARIA event. The full data set analysis (data cutoff: May 23, 2025) will further explore these findings.
Authors
- Curtis P. Schreiber
- Paul Ernest Schulz (ORCID: https://orcid.org/0000-0003-0676-002X)
- Daryl Jones
- David C. Weisman
- Michael Rosenbloom (ORCID: https://orcid.org/0000-0002-2768-9501)
- Christian Camargo
- Gregory Cooper
- Jose Soria‐Lopez
- Brooke Allen
- Samuel Giles
- Cara Leahy
- Courtney Adams
- Marwan N. Sabbagh
- Martin Sadowski
Institutions
- Allen Institute for Brain Science (US)
- Stone Clinic (US)
- Barrow Neurological Institute (US)
- University of Miami (US)
- Cancer Treatment Centers of America (US)
- Norton Healthcare (US)
- Abington Memorial Hospital (US)
- NYU Langone Health (US)
- Memorial Healthcare System (US)
- Rongsheng Petrochemical (China) (CN)
- Eisai (United States) (US)
- Memorial Hospital (US)
- The University of Texas Health Science Center at Houston (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70861_108599
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00